文献速递肿瘤 PET/CT骨显像与常规 SPECT

低己糖激酶-2表达相关假阴性18F-FDG PET/CT可作为多发性骨髓瘤潜在预后预测因子

Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-03-22

假阴性PET/CT见于12%患者,其至下一次治疗时间(TTNT)和至进展时间均优于阳性PET/CT患者,且与无高危PET/CT发现者相似,提示该现象不削弱基于PET/CT的预后判断。

要点

  • 低HK2表达相关假阴性PET/CT见于12%新诊断MM患者,其TTNT显著长于阳性PET/CT患者(P=0.035)。
  • 假阴性PET/CT患者PFS较阳性PET/CT患者呈延长趋势(P=0.071)。
  • 假阴性PET/CT患者TTNT和PFS与无高危PET/CT发现者相似,且显著长于高危PET/CT患者(P=0.013和0.047)。

核心结论

  • 低HK2表达相关假阴性18F-FDG PET/CT与新诊断多发性骨髓瘤患者相对更好的预后相关。
  • 该现象可能不会削弱已建立的基于PET/CT的预后判断。
  • 该现象或有助于在DWMRI显示骨髓瘤病灶的患者中识别疾病进展风险较低者。

研究设计与样本

  • 患者均在诱导治疗期间接受新型药物。
  • 按PET/CT阳性与全身弥散加权MRI(DWMRI)阳性的组合分为三组:DWMRI阴性、假阴性PET/CT、阳性PET/CT。

主要发现

  • 假阴性PET/CT见于12%的患者,这些患者年龄更大、有冒烟型多发性骨髓瘤临床病史、HK2表达水平低于阳性PET/CT患者。
  • 假阴性PET/CT患者TTNT较阳性PET/CT患者呈延长趋势(P=0.035),PFS亦呈延长趋势(P=0.071)。
  • 假阴性PET/CT患者TTNT和PFS与无已确立高危PET/CT发现的患者相似。
  • 假阴性PET/CT患者TTNT和PFS显著长于高危PET/CT患者(P=0.013和0.047)。

关键数值与推荐

  • 假阴性PET/CT定义为低HK2表达相关、PET/CT阴性而DWMRI阳性的状态。
  • 分组依据为PET/CT阳性与全身DWMRI阳性的组合。
  • 假阴性PET/CT发生率12%。
  • TTNT比较P=0.035,PFS比较P=0.071(假阴性vs阳性PET/CT)。
  • TTNT和PFS比较P=0.013和0.047(假阴性vs高危PET/CT)。

临床怎么用

  • 对新诊断多发性骨髓瘤患者,若DWMRI阳性而18F-FDG PET/CT阴性,应考虑低HK2表达相关假阴性可能。
  • 此类假阴性PET/CT结果不应简单视为预后不良,其预后可能相对较好。
  • 该现象可用于在DWMRI显示骨髓瘤病灶的患者中识别进展风险较低者。

局限性

  • 本研究为回顾性研究。
  • 假阴性PET/CT与阳性PET/CT比较的PFS差异P=0.071,未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: False-negative 18F-FDG PET/CT, which is associated with low hexokinase-2 (HK2) expression in multiple myeloma (MM), is a new concept that is relevant for diagnosis and treatment response assessment. This study aimed to investigate the prognostic relevance of low HK2 expression-associated false-negative PET/CT in patients with MM. METHODS: Ninety consecutive patients, with newly diagnosed MM, receiving novel agents during induction therapy were enrolled in this retrospective study. Patients were divided into three groups according to the combination of the positivity of PET/CT and whole-body diffusion-weighted magnetic resonance imaging (DWMRI), namely, negative DWMRI, false-negative PET/CT, and positive PET/CT. RESULTS: False-negative PET/CT was observed in 12% patients who were older, had documented clinical history of smouldering MM, and showed lower HK2 expression levels than the positive PET/CT patients. False-negative PET/CT patients showed a clear trend of longer time to next treatment (TTNT) and progression-free survival (PFS) than the positive PET/CT patients (P = 0.035 and 0.071, respectively). Furthermore, TTNT and PFS of false-negative PET/CT patients were similar to those of patients without established high-risk PET/CT findings and significantly longer than those of high-risk PET/CT patients (P = 0.013 and 0.047, respectively). CONCLUSIONS: This study showed, for the first time, that low HK2 expression-associated false-negative PET/CT was associated with relatively better prognosis in patients with newly diagnosed MM, suggesting that this phenomenon may not undermine the established PET/CT-based prognostication. Furthermore, this phenomenon may be useful for identifying patients at lower risk of disease progression among those with myelomatous lesions on DWMRI.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Abe Y, Ikeda S, Kitadate A, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019. PMID: 30903198. doi:10.1007/s00259-019-04312-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。